Critical Review: CASI Pharmaceuticals (NASDAQ:CASI) and Nexentis Technologies (NASDAQ:NXTS)

Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Insider & Institutional Ownership

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Nexentis Technologies has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Nexentis Technologies and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexentis Technologies N/A -304.79% -178.91%
CASI Pharmaceuticals -183.93% N/A -131.54%

Analyst Recommendations

This is a summary of current ratings for Nexentis Technologies and CASI Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexentis Technologies 1 0 0 0 1.00
CASI Pharmaceuticals 1 0 0 0 1.00

Earnings & Valuation

This table compares Nexentis Technologies and CASI Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nexentis Technologies $210,000.00 2.75 -$4.00 million ($96.07) -0.02
CASI Pharmaceuticals $26.85 million 0.10 -$39.26 million ($3.01) -0.07

Nexentis Technologies has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Nexentis Technologies beats CASI Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Nexentis Technologies

(Get Free Report)

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens.

About CASI Pharmaceuticals

(Get Free Report)

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China. The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.

Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.